Advances in Breast Cancer – Looking Back over the Year

Abstract

Treatment options as well as the characteristics for therapeutic decisions in patients with primary and advanced breast cancer are increasing in number and variety. New targeted therapies in combination with established chemotherapy schemes are broadening the spectrum, yet not every new, promising combination achieves a better result. New data from the field of pharmacogenomics point to prognostic and predictive factors that take not only the properties of the tumour but also the genetic disposition of the patient into consideration. Current therapeutic decision-making is thus based on a combination of classical clinical and modern molecular biomarkers. Health-economic concerns are also being taken into consideration more frequently, meaning political decisions may also become a factor. This review presents the trends over the past year.

Zusammenfassung

Die Behandlungsoptionen und auch die Charakteristika zur Therapieentscheidung der Patientin mit einem primären und fortgeschrittenen Mammakarzinom werden immer vielfältiger. Neue zielgerichtete Therapien in Kombination mit etablierten Chemotherapien erweitern das Spektrum, doch potenziell vielversprechende Kombinationen bringen nicht immer ein besseres Ergebnis. Neueste Daten aus der Pharmakogenomik weisen auf Prognose- und Prädiktivfaktoren hin, die nicht nur die Eigenschaften des Tumors, sondern auch die vererbbaren genetischen Eigenschaften der Patientin berücksichtigen. Die aktuelle Therapieentscheidung ist somit mittlerweile eine Kombination aus klassischerweise klinischen und modernen molekularen Biomarkern. Immer häufiger werden auch gesundheitsökonomische Aspekte berücksichtigt, sodass auch gesundheitspolitische Überlegungen eine Rolle spielen können. Diese Übersichtsarbeit stellt die Entwicklung des vergangenen Jahres dar.

Key words

breast cancer therapy - molecular biomarkers - targeted therapy - trastuzumab - T-DM1 - everolimus

Schlüsselwörter

Mammakarzinombehandlung - molekulare Biomarker - zielgerichtete Therapie - Trastuzumab - T-DM1 - Everolimus

• References

• 1 Strehl JD, Wachter DL, Fasching PA et al. Invasive breast cancer: recognition of molecular subtypes. Breast Care (Basel) 2011; 6: 258-264
• 2 Schmidt M, Fasching PA, Beckmann MW et al. Biomarkers in breast cancer – an update. Geburtsh Frauenheilk 2012; 72: 819-832
• 3 Fehm T, Janni W, Kummel S et al. Review: SABCS 2010–current treatment options for patients with breast cancer. Geburtsh Frauenheilk 2011; 71: 260-276
• 4 Kolberg HC, Luftner D, Lux MP et al. Breast cancer 2012–new aspects. Geburtsh Frauenheilk 2012; 72: 602-615
• 5 Kummel S, Kolberg HC, Luftner D et al. Breast cancer 2011–new aspects. Geburtsh Frauenheilk 2011; 71: 939-953
• 6 Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70
• 7 Shah SP, Roth A, Goya R et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486: 395-399
• 8 Ellis MJ, Ding L, Shen D et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486: 353-360
• 9 Fasching PA, Ekici AB, Adamietz BR et al. Breast cancer risk – genes, environment and clinics. Geburtsh Frauenheilk 2011; 71: 1056-1066
• 10 Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826
• 11 Badve S, Gray RJ, Baehner FL et al. Correlation between the DCIS Score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study. J Clin Oncol 2012; 30 (Suppl.) Abstr. 1005
• 12 McCormick B. RTOG 9804: A prospective randomized trial for “good risk” ductal carcinoma in situ (DCIS), comparing radiation (RT) to observation (OBS). J Clin Oncol 2012; 30 (Suppl.) Abstr. 1004
• 13 Gelmon KA, Boyle F, Kaufman B et al. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER-2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol 2012; 30: LBA671
• 14 Blackwell KL, Miles D, Gianni L et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. J Clin Oncol 2012; 30 (Suppl.) Abstr. LBA1
• 15 Verma S, Miles D, Gianni L et al. Updated overall survival results from EMILIA, a phase 3 study of trastuzumab emtansine (T-DM1) vs. capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer. Ann Oncol 2012; 23 (Suppl. 09) ixe5
• 16 von Minckwitz G, Eidtmann H, Rezai M et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366: 299-309
• 17 Untch M, Loibl S, Bischoff J et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012; 13: 135-144
• 18 Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379: 633-640
• 19 Robidoux A, Tang G, Rastogi P et al. Evaluation of lapatinib as a component of neoadjuvant therapy for HER-2+ operable breast cancer: NSABP protocol B-41. J Clin Oncol 2012; 30 (Suppl.) Abstr. LBA506
• 20 Duchnowska R, Dziadziuszko R, Czartoryska-Arlukowicz B et al. Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Res Treat 2009; 117: 297-303
• 21 Duchnowska R, Jassem J, Goswami CP et al. 13-gene signature to predict rapid development of brain metastases in patients with HER-2-positive advanced breast cancer. J Clin Oncol 2012; 30 (Suppl.) Abstr. 505
• 22 Liedtke C, Wolf MK, Kiesel L. New concepts for targeted systemic therapy in breast cancer. Geburtsh Frauenheilk 2010; 70: 625-633
• 23 Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-529
• 24 Piccart M, Noguchi S, Pritchard KI et al. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trial. J Clin Oncol 2012; 30 (Suppl.) Abstr. 559
• 25 Beck J, Rugo HS, Burris HA et al. BOLERO-2: Health-related quality-of-life in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane. J Clin Oncol 2012; 30 (Suppl.) Abstr. 539
• 26 Pritchard KI, Burris HA, Rugo HS et al. Safety of everolimus for women over 65 years of age with advanced breast cancer (BC): 12.5-mo follow-up of BOLERO-2. J Clin Oncol 2012; 30 (Suppl.) Abstr. 551
• 27 Gnant M, Baselga J, Rugo HS et al. Effects of everolimus (EVE) on disease progression in bone and bone markers (BM) in patients (pts) with bone metastases (mets). J Clin Oncol 2012; 30 (Suppl.) Abstr. 512
• 28 Oliveira M, Navarro A, De Mattos-Arruda L et al. PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts). J Clin Oncol 2012; 30 (Suppl.) Abstr. 509
• 29 Loi S, Michiels S, Lambrechts D et al. Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS) in early breast cancer (BC): results from the FinHER trial. J Clin Oncol 2012; 30 (Suppl.) Abstr. 507
• 30 Ellis MJ, Ding L, Shen D et al. Whole genome sequencing to characterize luminal-type breast cancer. J Clin Oncol 2012; 30 (Suppl.) Abstr. 503
• 31 Yates LR, Campbell PJ. Evolution of the cancer genome. Nat Rev Genet 2012; 13: 795-806
• 32 Hartkopf AD, Banys M, Krawczyk N et al. Circulating tumor cells in early-stage breast cancer. Geburtsh Frauenheilk 2011; 71: 1067-1072
• 33 Untch M, Gerber B, Mobus V et al. Zurich consensus: statement of German experts on St. Gallen conference 2011 on breast cancer (Zurich 2011). Geburtsh Frauenheilk 2011; 71: 381-390
• 34 Martin M, Lluch A, Ruiz A et al. Randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer (BC) comparing FAC with FAC followed by weekly paclitaxel: First efficacy analysis of the GEICAM/2003-02 trial. J Clin Oncol 2012; 30 (Suppl.) Abstr. 1001
• 35 Swain SM, Tang G, Geyer CE et al. NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC→paclitaxel (P) plus gemcitabine (G) with DD AC→P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. J Clin Oncol 2012; 30 (Suppl.) Abstr. LBA1000
• 36 Rugo HS, Barry WT, Moreno-Aspitia A et al. CALGB 40502/NCCTG N063H: randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2012; 30 (Suppl.) Abstr. CRA1002
• 37 Gennari A, Stockler M, Puntoni M et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 2011; 29: 2144-2149
• 38 Lux MP, Fasching PA, Loehberg CR et al. Health services research and health economy – quality care training in gynaecology, with focus on gynaecological oncology. Geburtsh Frauenheilk 2011; 71: 1046-1055
• 39 Lux MP, Reichelt C, Wallwiener D et al. Zoledronic acid – a cost-effective adjuvant therapy for patients with breast cancer. Results of the Zometa® cost-utility model for the German healthcare system based on the results of the ABCSG-12 study. Onkologie 2010; 33: 360-368
• 40 LLombarto A, Frassoldati A, Paija O et al. Effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow up. ASCO Breast Cancer Symposium 2009.
• 41 Lux MP, Reichelt C, Wallwiener D et al. Breast cancer: bisphosphonates in the adjuvant – also from a health point of view a useful therapy. Geburtsh Frauenheilk 2010; 70: 592-595
• 42 Xue M, Fishman P, Botteman M. Cost-effectiveness of zoledronic acid (ZOL) in postmenopausal women with early breast cancer receiving adjuvant letrozole. J Clin Oncol 2012; 30 (Suppl.) Abstr. 553
• 43 Hughes LL, Wang M, Page DL et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009; 27: 5319-5324
• 44 Lück HJ, Lux MP. Aktuelle Empfehlungen zur Therapie primärer und fortgeschrittener Mammakarzinome State of the Art 2012. Brustkrebs: Spezielle Situationen. Kommission Mamma, Arbeitsgemeinschaft Gynäkologische Onkologie e.V., Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e.V., Deutsche Krebsgesellschaft e.V.; 2012
• 45 Reeder-Hayes KE, Wheeler SB, Biddle AK. Cost-effectiveness of adjuvant radiotherapy for older women with early hormone-receptor positive breast cancer. J Clin Oncol 2012; 30 (Suppl.) Abstr. 6096
• 46 Wang Z, Li X, Faria C. Characterization of health care resource utilization and costs in women with metastatic breast cancer in Medicaid. J Clin Oncol 2012; 30 (Suppl.) Abstr. e16521
• 47 Refaat T, Choi M, Gaber G et al. Cost-effectiveness analysis using a Markov model assessing the addition of bevacizumab to paclitaxel in HER-2-negative metastatic breast cancer patients. J Clin Oncol 2012; 30 (Suppl.) Abstr. 1069
• 48 Twelves C, Loesch D, Blum JL et al. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physicianʼs choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2012; 28 (Suppl.) Abstr. CRA1004^
• 49 Montero AJ, Avancha KKVR, Gluck S et al. Cost-effectiveness analysis of eribulin (E) versus treatment of physicianʼs choice (TPC) in patients (pts) with pretreated metastatic breast cancer (MBC). J Clin Oncol 2012; 30 (Suppl.) Abstr. e16525